NeoTX Therapeutics
Feb 20, 2020
Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust
Incyte meets endpoint in the second pivotal atopic dermatitis clinical trial A second phase 3 trial of Incyte’s ruxolitinib cream in atopic dermatitis has hit its primary endpoint. The back-to-back pivotal successes irked Incyte to talk to regulators regarding upcoming of the JAK inhibitor to market. Ruxoliti...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
